- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05300048
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35429
- University of Alabama
-
-
California
-
Anaheim, California, United States, 92801
- Pacific Cancer Specialists
-
Los Angeles, California, United States, 90067
- Valkyrie Clinical Trials
-
Newport Beach, California, United States, 92663
- HOAG Memorial Hospital Presbyterian
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Community Health Network, Inc.
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Mayo Clinic - Rochester
-
-
New Jersey
-
Belleville, New Jersey, United States, 07109
- New Jersey Cancer Care, PA
-
Englewood, New Jersey, United States, 07631
- Englewood Health
-
-
New York
-
Lake Success, New York, United States, 11042
- Northwell Health
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Greenville, North Carolina, United States, 27858
- East Carolina University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Avera Cancer Institute
-
-
Texas
-
Beaumont, Texas, United States, 77701
- Baptist Hospitals of Southeast Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern
-
Houston, Texas, United States, 77030
- Oncology Consultants, PA
-
Kingwood, Texas, United States, 77339
- Lumi Research
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to provide written informed consent.
- Age ≥18 at Visit -1 (screening).
Histologically or cytologically confirmed recurrent solid tumors.
Cohort 1a: any extracranial solid tumor (may include EC, ovarian clear cell, or ovarian endometrioid carcinoma if subject is not eligible for nab-paclitaxel in Cohort
1b)
- Cohort 1b: either recurrent or persistent endometrial adenocarcinoma (EC) with the following histologic epithelial cell types: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma, and carcinosarcoma or; ovarian cancer (OC) with the primary tumor having ≥ 50% clear cell histomorphology or ovarian clear cell or ovarian endometrioid carcinoma.
- Cohort 2: adenocarcinoma of the colon or rectum.
- Cohort 3: recurrent or persistent endometrial adenocarcinoma with the following histologic epithelial cell types as described for Cohort 1b
- Cohort 4: OC primary tumor carcinomas as described for Cohort 1b
- Tumor must harbor an activating mutation in the PIK3CA gene with or without PTEN loss, either previously documented or determined during screening.
- Fresh or archival tumor biopsy with sufficient material to be sent to the designated laboratory for PD analyses. For subjects who consent to future research, an additional 5 slides from a surgical specimen or biopsy is required.
- Cohort 1a - Dose Modification (subjects with any solid tumor): failed, were intolerant of, or ineligible for no more than three prior lines of therapy (LOT) for advanced/metastatic disease or refused SOC therapy.
- For all cohorts, in the unlikely scenario that a subject refused all available SOC they may proceed with trial. These subjects would be regarded as having 0 prior LOT.
Cohorts 1b, 2, 3, and 4 - failed, were intolerant of, ineligible for, or have refused SOC therapy for advanced/metastatic disease (AJCC stage III and IV) and:
- Cohort 2 (subjects with colorectal cancer): Have failed no more than two prior LOT for metastatic CRC.
- Cohort 1b, and Cohort 3 (subjects with EC): Have no more than three prior chemotherapeutic regimens for management of endometrial carcinoma (neo-adjuvant and/or adjuvant chemotherapy will be counted as one prior LOT). Prior hormonal therapy will not count as a systemic regimen.
- Cohort 1b, and Cohort 4 (subjects with clear cell or endometrioid OC): Subjects must have had no more than three prior chemotherapeutic regimens for management of ovarian carcinoma. Prior hormonal therapy will not count as a systemic regimen.
- Life expectancy of at least 3 months.
- At least one measurable lesion (as defined by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1).
- ECOG PS of 0 to 1.
Adequate organ function
- Absolute neutrophil count (ANC) ≥1.0 × 10^9/L or ≥1.5 x 10^9/L if planned to be treated with nab-paclitaxel, platelet count ≥75 × 10^9/L, and hemoglobin ≥8.5 gm/dL (may be transfused to reach this hemoglobin level unless due to blood loss).
- Liver transaminases (AST and ALT) ≤2.5 × upper limit of normal (ULN) (<5 × ULN if liver metastases are present), and total bilirubin ≤1.5 × ULN (<3 x ULN if subject has Gilbert Syndrome).
- INR ≤1.5 x ULN unless subject is on anticoagulants that would affect the INR, then INR must be in the desired therapeutic range as judged by the Investigator.
- Albumin level ≥3.0 mg/dL or ≥ the lower limit of normal.
- Renal: Serum creatinine ≤2 x ULN
- Ability to take PO medication, be willing to adhere to study procedures and Study Intervention administration, and receive, consume, and comply with Study ISD.
- For women of child-bearing potential, a negative serum pregnancy test collected at screening (Visit-1) and negative urine pregnancy test collected at baseline (Visit-1) and use of physician-approved method of birth control from the time of the pregnancy test performed at screening to 90 days following the last administration of Study Drug or, if applicable, 6 months following the last administration of nab-paclitaxel.
- Male subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 90 days following the last administration of Study Drug.
Exclusion Criteria:
- Diagnosis of primary malignant brain tumor.
- Has had serabelisib, alpelisib, or other PI3K inhibitor.
- Leptomeningeal disease and symptomatic or untreated brain metastases.
- Diagnosis of, or requiring treatment for, another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 90 days prior to the first dose of Study Drug).
- Is less than 21 days from therapeutic radiation or chemotherapy prior to the first day of dosing with Study Drug and has not recovered to Grade ≤ 1 from all clinically significant toxicities related to prior therapies.
- For subjects receiving nitrosoureas or mitomycin C, the subject is < 6 weeks from last dose. For monoclonal antibody therapy, the subject is < 1 half-life or <4 weeks from the last dose.
- Chronic, systemically administered glucocorticoids in doses equivalent to >5 mg prednisone daily. Replacement corticosteroids for adrenal insufficiency are permitted.
- Diabetes mellitus requiring insulin or insulin secretagogue therapy.
- Poorly controlled diabetes mellitus defined as glycosylated hemoglobin A1c (HbA1c) >7.5% or fasting blood sugar >160 mg/ dL.
- Known impaired cardiac function or clinically significant cardiac disease.
- QTcF interval >470 msec found at screening.
- Myocardial infarction, cardiac stent placement, or unstable angina within 6 months before the first administration of Study Drug.
- Have clinically significant peripheral vascular disease.
- Manifestations of malabsorption
- Other clinically significant comorbidities.
- Pregnant (positive serum pregnancy test), planning to become pregnant during the study, or breastfeeding/planning to breastfeed during the study.
- Have taken strong CYP3A4 inducers/inhibitors within 7 days before the first administration of serabelisib or have conditions that require the concomitant use of CYP3A4 inducers/inhibitors.
- Untreated or poorly controlled, gastro-esophageal reflux disease.
- Have taken histamine-H2 receptor antagonists within 12 hours before the first administration of serabelisib.
- Have taken PPI within 7 days or 5 half-lives (whichever is the shorter duration) before the first administration of serabelisib or are anticipated to need PPI during the study.
- Have taken neutralizing antacids within 4 hours before the first administration of serabelisib or are anticipated to need frequent antacid use during the study.
- Subjects with poorly controlled human immunodeficiency virus, hepatitis B virus, and/or hepatitis C virus infections.
- Known allergies to nab-paclitaxel or excipients, serabelisib or excipients or the ISD
- Severe, uncontrolled gout.
- A BMI <18.5 kg/m2, or serious or refractive cachexia or anorexia that, in the Investigator's opinion, realistically prohibits subjects from having energy or appetite sufficient to reliably engage in a strict ISD regimen for an extended time.
- Any condition that renders the subject unable to satisfactorily chew, swallow, digest, or tolerate (i.e., persistent diarrhea) the majority of foods and liquids of the Study ISD.
- History of severe nephrolithiasis requiring urologic intervention.
- Participation in a diet or weight loss plan within 10 days prior to the first administration of Study Drug.
- Severe constipation or condition where exacerbation of constipation is not advisable (eg, small bowel obstruction history).
- History of anaphylaxis from food allergy or other disease state requiring avoidance of a particular food, such as celiac disease.
- Diagnosed eating disorder in the past 10 years.
- Unwilling to take a non-vegan or non-vegetarian diet.
- Peripheral neuropathy ≥ CTC Grade 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1a - Dose Modification without nab-paclitaxel
Subjects with any solid tumor will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months
|
serabelisib administered orally
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
|
Experimental: Cohort 2 - Expansion Colorectal Cancer
Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months
|
serabelisib administered orally
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
|
Experimental: Cohort 3 - Expansion Endometrial Cancer
Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months.
If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.
|
serabelisib administered orally
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
nab-paclitaxel administered intravenously weekly
|
Experimental: Cohort 4 - Expansion Ovarian Clear Cell or Ovarian Endometrioid Carcinoma
Subjects will receive dose of serabelisib as determined from Cohorts 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months.
If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.
|
serabelisib administered orally
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
nab-paclitaxel administered intravenously weekly
|
Experimental: Cohort 1b - Dose Modification with Nab-Paclitaxel
Subjects with endometrial cancer, ovarian clear cell or ovarian endometriod carcinoma will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months.
In addition, these subjects will receive nab-paclitaxel intravenously weekly.
|
serabelisib administered orally
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
nab-paclitaxel administered intravenously weekly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohorts 1a/1b: Evaluate safety
Time Frame: Through study completion, up to 12 months.
|
Incidence of related AEs
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b: Evaluate compliance
Time Frame: Through study completion, up to 12 months.
|
Compliance of Study intervention
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Cmax.
Time Frame: Through study completion, up to 12 months.
|
Standard pharmacokinetic parameters (Cmax)
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Tmax.
Time Frame: Through study completion, up to 12 months.
|
Standard pharmacokinetic parameters (Tmax).
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring AUC.
Time Frame: Through study completion, up to 12 months.
|
Standard pharmacokinetic parameters (AUC).
|
Through study completion, up to 12 months.
|
Cohorts 2, 3, 4: Use the Objective Response Rate (ORR) to assess the antitumor efficacy of serabelisib in combination with a Study ISD.
Time Frame: Through study completion, an average of 8 months.
|
Proportion of subjects who have best overall response of either complete response (CR) or partial response (PR)
|
Through study completion, an average of 8 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring ORR.
Time Frame: Through study completion, up to 12 months.
|
Proportion of subjects who have best overall response of either CR or PR, as determined by each site.
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring PFS.
Time Frame: Through study completion, up to 12 months.
|
Time from date of first dose of Study Drug (Visit 1) to the date of first evidence of disease progression or death from any cause (whichever occurs first).
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring OS.
Time Frame: Through study completion, up to 12 months.
|
Overall survival (OS) and landmark survival.
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring DCR.
Time Frame: Through study completion, up to 12 months.
|
Disease control rate (DCR; CR + PR + stable disease [SD])
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Confirm safety
Time Frame: Through study completion, up to 12 months.
|
Incidence of related AEs
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Confirm the compliance of study intervention.
Time Frame: Through study completion, up to 12 months.
|
Compliance of Study intervention
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring OS).
Time Frame: Through study completion, up to 12 months.
|
OS and landmark survival
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring DoR).
Time Frame: Through study completion, up to 12 months.
|
DoR
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring DCR).
Time Frame: Through study completion, up to 12 months.
|
DCR (CR+PR+SD)
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.
Time Frame: Through study completion, up to 12 months.
|
Standard PK Parameters (Cmax) in plasma.
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.
Time Frame: Through study completion, up to 12 months.
|
Standard PK Parameters (Tmax) in plasma
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.
Time Frame: Through study completion, up to 12 months.
|
Standard PK Parameters (AUC) in plasma
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.
Time Frame: Through study completion, up to 12 months.
|
Serabelisib concentration in tumor tissue
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring DoR.
Time Frame: Through study completion, up to 12 months.
|
Duration of response (DoR)
|
Through study completion, up to 12 months.
|
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring PFS).
Time Frame: Through study completion, up to 12 months.
|
Time from the date of first dose of Study Drug (Visit 1) to the date of first evidence of disease progression or death from any cause (whichever occurs first)
|
Through study completion, up to 12 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.
Time Frame: Through study completion, up to 12 months.
|
Change in PD markers (insulin)
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.
Time Frame: Through study completion, up to 12 months.
|
Change in PD markers (glucose)
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.
Time Frame: Through study completion, up to 12 months.
|
Change in biomarkers of insulin-PI3K signaling
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.
Time Frame: Through study completion, up to 12 months.
|
Changes in tumor marker levels.
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b, 2, 3, 4: Assessment of immune markers in response to study intervention.
Time Frame: Through study completion, up to 12 months.
|
Assessment of immune markers in PBMCs throughout study.
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b, 2, 3, 4: Assessment of genetic predictors of efficacy.
Time Frame: Through study completion, up to 12 months.
|
Analysis into whether the genetic status of the patient predicts a positive or negative therapeutic response (efficacy).
|
Through study completion, up to 12 months.
|
Cohorts 1a/1b, 2, 3, 4: Assessment of genetic predictors of toxicity.
Time Frame: Through study completion, up to 12 months.
|
Analysis into whether the genetic status of the patient predicts susceptibility to AEs (toxicity).
|
Through study completion, up to 12 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vicky Makker, Memorial Sloan Kettering Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SER-ISD1-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on Serabelisib
-
Millennium Pharmaceuticals, Inc.CompletedMetastatic Solid TumorsUnited States, Spain, United Kingdom
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Nonhematologic MalignanciesUnited States, Spain, United Kingdom
-
Millennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung CancerUnited States, Netherlands, Canada
-
Millennium Pharmaceuticals, Inc.Completed
-
Petra PharmaUnknownBreast Cancer | Head and Neck Cancer | Lung Cancer | Endometrial Cancer | Colo-rectal Cancer
-
Joyce O'ShaughnessyTakedaCompletedTriple Negative Breast CancerUnited States
-
Millennium Pharmaceuticals, Inc.CompletedClear-cell Metastatic Renal Cell CarcinomaSpain, Czechia, United States, Canada, Italy, United Kingdom, France, Poland
-
Millennium Pharmaceuticals, Inc.TerminatedAdvanced and Metastatic Gastric or Gastroesophageal AdenocarcinomaUnited States, Spain
-
Millennium Pharmaceuticals, Inc.European Network of Translational Research in Ovarian Cancer - EUTROC; European...CompletedEndometrial NeoplasmsUnited States, Canada, Netherlands, Spain, Belgium, United Kingdom, Italy, Australia, Germany, Norway
-
Avera McKennan Hospital & University Health CenterActive, not recruitingAdvanced Solid TumorUnited States